Restricted accessResearch articleFirst published online 2022-05
Associations of Serum Vitamin D Level with Sarcopenia,Non-Alcoholic Fatty Liver Disease (NAFLD),and Sarcopenia in NAFLD Among People Aged 50 Years and Older: The Korea National Health and Nutrition Examination Survey IV–V
The role of serum 25-hydroxyvitamin D [25(OH)D] levels in the development of sarcopenia in non-alcoholic fatty liver disease (NAFLD) remains controversial. We investigated the association between vitamin D levels, occurrence of sarcopenia, NAFLD, and sarcopenia in NAFLD in adults aged >50 years.
Methods:
This study used data pertaining to 5396 adults aged >50 years (1870 men and 3526 women) from the 2008–2011 Korea National Health and Nutrition Examination Survey. Appendicular skeletal muscle mass adjusted by weight (ASM/Wt) was used to diagnose sarcopenia, and NAFLD was diagnosed using the NAFLD fat score.
Results:
The lowest quintile of serum 25(OH)D level (4.85–15.26 ng/mL) was associated with an increased occurrence of sarcopenia [odds ratio (OR) 2.65; 95% confidence interval (CI) 1.64–4.27], NAFLD (OR 1.82; 95% CI 1.19–2.96), and sarcopenia in NAFLD (OR 2.25; 95% CI 1.26–4.03) in men. In women, sarcopenia (OR 1.80; 95% CI 1.29–2.51) was also significantly associated with serum vitamin D levels, whereas high levels of vitamin D were not significantly related to NAFLD.
Conclusions:
Serum vitamin D levels are associated with sarcopenia, NAFLD, and sarcopenia in NAFLD. Vitamin D level can be a useful marker of sarcopenia and NAFLD, especially in men.
Get full access to this article
View all access options for this article.
References
1.
Cruz-JentoftAJ, BahatG, BauerJ, et al.Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing, 2019; 48:601.
2.
WalrandS, GuilletC, SallesJ, et al.Physiopathological mechanism of sarcopenia. Clin Geriatr Med, 2011; 27:365–385.
3.
CalvaniR, MiccheliA, LandiF, et al.Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging, 2013; 2:38.
4.
FisherN, PendergastD, CalkinsE. Maximal isometric torque of knee extension as a function of muscle length in subjects of advancing age. Arch Phys Med Rehabil, 1990; 71:729–734.
5.
BrianAD, SvenAH, BrianER, et al.Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep, 2018; 8:11369.
6.
GraffyPM, LiuJ, PickhardtPJ, et al.Deep learning-based muscle segmentation and quantification at abdominal CT: Application to a longitudinal adult screening cohort for sarcopenia assessment. Brit J Radiol, 2019; 92:20190327.
7.
BauerJ, MorleyJE, ScholsAM, et al.Sarcopenia: A time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle, 2019; 10:956–961.
8.
DionyssiotisY. Frailty and Sarcopenia: Onset, Development and Clinical Challenges. Norderstedt, Germany: BoD–Books on Demand; 2017.
9.
De FréC, De FréM, KwantenW, et al.Sarcopenia in patients with non-alcoholic fatty liver disease: Is it a clinically significant entity?. Obes Rev, 2019; 20:353–363.
10.
LiAA, KimD, AhmedA. Association of sarcopenia and NAFLD: An Overview. Clin Liver Dis, 2020; 16:73.
11.
RietmanA, SchwarzJ, Tomé D, et al. High dietary protein intake, reducing or eliciting insulin resistance?. Eur J Clin Nutr, 2014; 68:973.
12.
LeeY, JungKS, KimSU, et al.Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol, 2015; 63:486–493.
13.
LisaC, SusanSH. Vitamin D and its role in skeletal muscle. Calcif Tissue Int, 2013; 92:151–162.
14.
McCormickR, VasilakiA. Age-related changes in skeletal muscle: Changes to life-style as a therapy. Biogerontology, 2018; 19:519–536.
15.
VisserM, DeegD, LipsP. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab, 2003; 88:5766–5772.
16.
LisaC, Mauricio da SilvaMorais, Lara KPark, et al.Multi-step immunofluorescent analysis of vitamin D receptor loci and myosin heavy chain isoforms in human skeletal muscle. J Mol Histol, 2010; 41:137–142.
17.
BarchettaI, CarottiS, LabbadiaG, et al.Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: Relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology, 2012; 56:2180–2187.
18.
EliadesM, SpyrouE, AgrawalN, et al.Meta-analysis: Vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2013; 38:246–254.
19.
KweonS, KimY, JangM, et al.Data resource profile: The Korea national health and nutrition examination survey (KNHANES). Int J Epidemiol, 2014; 43:69–77.
20.
LeeS, RyuKS, KangHYJ, et al.Risk factors of undiagnosed diabetes mellitus among Korean adults: A national cross-sectional study using the KNHANES data. Int J Environ Res Public Health, 2021; 18:1195.
21.
LimS, KimJ, YoonJ, et al.Sarcopenic obesity: Prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care, 2010; 33:1652–1654.
22.
BaumgartnerRN, KoehlerKM, GallagherD, et al.Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol, 1998; 147:755–763.
23.
CawthonPM, PetersKW, ShardellMD, et al.Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci, 2014; 69:567–575.
24.
KotronenA, PeltonenM, HakkarainenA, et al.Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology, 2009; 137:865–872.
25.
LeeY, KimS, SongK, et al.Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). Hepatology, 2016; 63:776–786.
26.
WillettW. Nutritional Epidemiology. Oxford, England: Oxford University Press; 2012.
27.
CameySA, TormanVB, HirakataVN, et al.Bias of using odds ratio estimates in multinomial logistic regressions to estimate relative risk or prevalence ratio and alternatives. Cad Saude Publ, 2014; 30:21–29.
28.
OkuboT, AtsukawaM, TsubotaA, et al.Relationship between serum vitamin D level and sarcopenia in chronic liver disease. Hepatol Res, 2020; 50:588–597.
29.
HongH, HwangS, ChoiH, et al.Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study. Hepatology, 2014; 59:1772–1778.
30.
YuR, ShiQ, LiuL, et al.Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: A meta-analysis. BMC Gastroenterol, 2018; 18:51.
31.
KimKM, JangHC, LimS. Differences among skeletal muscle mass indices derived from height-, weight-, and body mass index-adjusted models in assessing sarcopenia. Korean J Intern Med, 2016; 31:643–650.
32.
HyppönenE, BoucherBJ, BerryDJ, et al.25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes, 2008; 57:298–305.
33.
ParkJ, Tirupathi PichiahP, ChaY. Vitamin D and metabolic diseases: Growing roles of vitamin D. J Obes Metab Syndr, 2018; 27:223–232.
34.
AwadAB, AlappatL, ValerioM. Vitamin d and metabolic syndrome risk factors: Evidence and mechanisms. Crit Rev Food Sci Nutr, 2012; 52:103–112.
35.
ZhangY, JiangX, LiX, et al.Serum vitamin D levels and risk of liver cancer: A systematic review and dose-response meta-analysis of cohort studies. Nutr Cancer, 2020:1–9.
36.
ColombiniA, Brayda-BrunoM, FerinoL, et al.Gender differences in the VDR-FokI polymorphism and conventional non-genetic risk factors in association with lumbar spine pathologies in an Italian case-control study. Int J Mol Sci, 2015; 16:3722–3739.
37.
NelsonJE, RothCL, WilsonLA, et al.Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: Possible role for MAPK and NF-κB?. Am J Gastroenterol, 2016; 111:852–863.
38.
ChenL, ChenR, WangH, et al.Mechanisms linking inflammation to insulin resistance. Int J Endocrinol, 2015; 2015:508409.
39.
DingC, WildingJP, BingC. 1,25-dihydroxyvitamin D3 protects against macrophage-induced activation of NFκB and MAPK signaling and chemokine release in human adipocytes. PLoS One, 2013; 8:e61707.
40.
MuttSJ, KarhuT, LehtonenS, et al.Inhibition of cytokine secretion from adipocytes by 1,25- dihydroxyvitamin D via the NF-κB pathway. FASEB J, 2012; 26:4400–4407.
41.
ParkD, KwonH, OhS, et al.Is vitamin D an independent risk factor of nonalcoholic fatty liver disease? A cross sectional study of the healthy population. J Korean Med Sci, 2017; 32:95–101.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
